Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
Open accessThe DOI matches its Crossref record; 64 of the 70 references it cites were found in a registry or an index, and 6 are not checked yet; 19 of the 29 sources its claims cite were checked for support.
Abstract
Another benefit of dietary fiber: The gut microbiome can modulate the immune system and influence the therapeutic response of cancer patients, yet the mechanisms underlying the effects of microbiota are presently unclear. Spencer et al . add to our understanding of how dietary habits affect microbiota and clinical outcomes to immunotherapy. In an observational study, the researchers found that melanoma patients reporting high fiber (prebiotic) consumption had a better response to checkpoint inhibitor immunotherapy compared with those patients reporting a low-fiber diet. The most marked benefit was observed for those patients reporting a combination of high fiber consumption and no use of over-the-counter probiotic supplements. These findings provide early insights as to how diet-related factors may influence the immune response. —PNK
Verified 2026-10-05 · 6 references not checked yet
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 0 Not valid · 3 Not checked · 41 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Gut bacteria modulate the response to immune checkpoint blockade (ICB) treatment in cancer”
§ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response > Abstract
What the sources say
- Not checked yetcites [2] Routy B, Science 359, 91– 97 (2018). 29097494 source
- Supportedcites [3] Matson V, Science 359, 104– 108 (2018). 29302014 PMC6707353 source
The supplied Abstract passage reports an association between gut microbial composition and clinical response to anti-PD-1 therapy in metastatic melanoma patients. It also reports that transferring responder-associated microbiota improved anti-PD-L1 efficacy in mice, supporting the claim that gut bacteria can modulate response to checkpoint blockade. (LLM, conf=0.91)
- Partly supportedcites [4] Gopalakrishnan V, Science 359, 97– 103 (2018). 29097493 PMC5827966 sourceExperimental — accuracy not yet measured
The paper’s concluding passage says the gut microbiome may modulate responses to anti-PD-1 immunotherapy in melanoma patients. The citing sentence states this more broadly and definitively for immune checkpoint blockade in cancer; the paper’s patient findings are limited to melanoma and anti-PD-1 treatment. Page numbers were not provided in our copy. (LLM, conf=0.85)
- Partly supportedcites [5] Frankel AE, Neoplasia 19, 848– 855 (2017). 28923537 PMC5602478 sourceExperimental — accuracy not yet measured
The Introduction reports that gut microbiota affect checkpoint-therapy responses in preclinical mouse models, and the Results find different bacterial species enriched in melanoma patients who responded to treatment. The human findings are associations, however; the paper says the mechanism of immune enhancement by these bacteria in humans remains unknown. Thus it does not establish that gut bacteria modulate treatment response in cancer patients. (LLM, conf=0.84)
- Supportedcites [6] Peters BA, Genome Med 11, 61 (2019). 31597568 PMC6785875 source
The Conclusions state that the pilot study supports the notion that gut microbiota modulate immunotherapy response in melanoma patients. The Background identifies the treatments studied as PD-1 and CTLA-4 checkpoint inhibitors, matching the claim’s reference to immune checkpoint blockade. (LLM, conf=0.91)
- Partly supportedcites [7] Andrews MC, Nat. Med 27, 1432– 1441 (2021). 34239137 PMC11107795 sourceExperimental — accuracy not yet measured
The Main Text reports that several gut bacterial taxa differed between melanoma patients who did and did not respond to combined checkpoint blockade, with related associations in mouse tumor models (page unavailable). This supports a link between gut bacteria and treatment response, but the patient findings are associations; they do not establish that bacteria modulate response in cancer patients generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“given the known impact of these on ICB response (32)”
§ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response > Abstract
What the sources say
- Partly supportedcites [32] Pinato DJ, JAMA Oncol 5, 1774– 1778 (2019). 31513236 PMC6743060 sourceExperimental — accuracy not yet measured
The Key Points report that antibiotics given within 30 days before immune checkpoint inhibitor therapy were associated with a higher risk of disease refractory to treatment. The claim is broader than the finding: the paper reports an observational association for prior antibiotic use, while its Limitations section says concurrent antibiotic use was not associated with response. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“however, this is not unexpected given the known challenges of isolating associations of specific dietary components from other factors known to affect the gut microbiota in observational human cohorts (33, 34).”
§ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response > Abstract
What the sources say
- Supportedcites [33] Klurfeld DM, Am. J. Physiol. Endocrinol. Metab 315, E1087– E1097 (2018). 30130151 PMC6415710 source
The WORKSHOP SUMMARY ('Focus on human studies of the colonic microbiome') states numerous challenges in characterizing diet effects on the human gut microbiome, including poor adherence, inaccurate characterization of dietary intake/composition, and that human observational studies generally point only to associations, with logistical challenges in large cohort studies. The same summary notes that diets high in protein or fat are necessarily low in carbohydrates, 'making it almost impossible to attribute causality to an individual macronutrient,' and lists nondietary factors (stress, exercise, smoking, coffee, personality) plus marked interindividual variation that must be recorded. The table under 'Choice of species depends on question(s) asked.' adds that cross-sectional studies cannot prove causality and that intake recording is relatively inaccurate. Together these support the paraphrase that isolating specific dietary components from other microbiota-affecting factors in observational human cohorts is challenging. (LLM, conf=0.87)
- Not checked yetcites [34] Makki K, Deehan EC, Walter J, Bäckhed F, Cell Host Microbe 23, 705– 715 (2018). 29902436 source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Given that many of the response-associated bacteria identified in our cohort have known roles in starch degradation and fiber fermentation (25–29)”
§ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response > Abstract
What the sources say
- Supportedcites [25] Flint HJ, Scott KP, Duncan SH, Louis P, Forano E, Gut Microbes 3, 289– 306 (2012). 22572875 PMC3463488 source
The paper’s Firmicutes sections describe starch utilization by Roseburia and Eubacterium rectale and plant-fiber polysaccharide utilization by Roseburia intestinalis and other gut bacteria (page numbers unavailable). The citation supports the bacteria’s known roles; identifying which bacteria were response-associated in the citing authors’ cohort is the citing authors’ own observation. (LLM, conf=0.86)
- Partly supportedcites [26] den Besten G, J. Lipid Res 54, 2325– 2340 (2013). 23821742 PMC3735932 sourceExperimental — accuracy not yet measured
In “The composition of gut microbiota” (page unavailable), the review identifies Bacteroidetes as fermenters of nondigestible carbohydrates, supporting a general role for gut bacteria in fiber fermentation. It does not identify the citing paper’s response-associated bacteria or establish that many of them degrade starch. (LLM, conf=0.84)
- Partly supportedcites [27] Poeker SA, Sci. Rep 8, 4318 (2018). 29531228 PMC5847601 sourceExperimental — accuracy not yet measured
The Results and Discussion describe bacterial responses to dietary fibers and identify taxa involved in fermenting or degrading them, including inulin-degrading Ruminococcaceae and Prevotella fermenting complex polysaccharides. The paper does not establish a role in starch degradation for these bacteria. Which bacteria were identified in the citing authors’ cohort is their own finding, not a finding attributed to this source. (LLM, conf=0.84)
- Partly supportedcites [28] So D, Am. J. Clin. Nutr 107, 965– 983 (2018). 29757343 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says Bifidobacterium and Lactobacillus utilize prebiotic fibers as substrates and discusses their fermentation preferences, supporting the fiber-fermentation part. The paper does not establish starch-degradation roles for many bacteria; its References list a work on Ruminococcus bromii and resistant-starch degradation, but that does not substantiate the broader claim. (LLM, conf=0.82)
- Supportedcites [29] Desai MS, Cell 167, 1339– 1353. e21 (2016). 27863247 PMC5131798 source
The Results describe testing gut bacteria for growth on dietary-fiber polysaccharides and identifying which bacteria use each carbohydrate. The supplemental figure (Additional information; page unavailable) identifies several species as plant-fiber and starch degraders and depicts short-chain fatty acid production from plant fiber. The cited paper supports those functional roles; the statement that the bacteria were response-associated in the citing authors’ cohort is their own framing. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The observed protective effect of dietary fiber intake in relation to PFS and response remained consistent among the subset of patients treated with anti–PD-1 monotherapy, with the exclusion of patients reporting recent antibiotic use given the known impact of these on ICB response (32) (tables S11 and S12).”
§ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response > Abstract
What the sources say
- Supportedcites [32] Pinato DJ, JAMA Oncol 5, 1774– 1778 (2019). 31513236 PMC6743060 source
The citation is attached to the rationale for excluding patients with recent antibiotic use, not to the citing authors’ dietary-fiber findings. The Results report that prior antibiotic therapy was associated with poorer response to immune checkpoint inhibitor treatment; the paper distinguishes this from concurrent antibiotic therapy. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
33 more claims · 1 with their cited sources checked
Create a free account to see all 52 claims and to verify the 10 references still open.
- Probably not a substantial claim. 8
- It may state two separate claims as one. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fiber-rich, plant-based diets have the opposite effect, nurturing Bifidobacterium and Lactobacillus, increasing butyrate producers like Roseburia and Eubacterium rectale, and shielding against obesity and insulin resistance via SCFA signaling.15,70,81–83”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical studies have linked deficient SCFA production to conditions such as graft-versus-host disease and poor responses to cancer immunotherapies, spurring interest in SCFA supplementation or diets to restore microbial balance.15,77,88,146,147”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“supporting a potential benefit of microbially produced SCFAs and an adjuvant role of fiber for ICB7,25.”
From Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, correlations have been drawn across cancer indications and geographical sites between the taxonomic composition of the gut (and to some degree tumor) microbiota, and ICI responses in patients with melanoma and other cancers.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second, exposures including medications, especially antibiotics and proton pump inhibitors, and diet that shape the microbiota are associated with ICI responses in patient cohorts and preclinical models.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [13]
Experimental — accuracy not yet measured
28 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
DADA2: High–resolution sample inference from Illumina amplicon data
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016) · Nature Methods · doi:10.1038/nmeth.3869 · Cited by 35,698
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
The SILVA ribosomal RNA gene database project: improved data processing and web-based tools
Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., & Glöckner, F. O. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1219 · Cited by 33,055
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
lmerTest Package: Tests in Linear Mixed Effects Models
Kuznetsova, A., Brockhoff, P. B., & Christensen, R. H. B. (2017) · Journal of Statistical Software · doi:10.18637/jss.v082.i13 · Cited by 24,346
Naïve Bayesian Classifier for Rapid Assignment of rRNA Sequences into the New Bacterial Taxonomy
Wang, Q., Garrity, G. M., Tiedje, J. M., & Cole, J. R. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.00062-07 · Cited by 19,885
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
Research works printed but not linked: 1
- H. Mallick A. Rahnavard L. J. McIver S. Ma Y. Zhang L. H. Nguyen T. L. Tickle G. Weingart B. Ren E. H. Schwager S. Chatterjee K. N. Thompson J. E. Wilkinson A. Subramanian Y. Lu L. Waldron J. N. Paulson E. A. Franzosa H. C. Bravo C. Huttenhower Multivariable Association Discovery in Population-scale Meta-omics Studies. bioRxiv 2021.01.20.427420 [Preprint] (2021). .10.1101/2021.01.20.427420 2021.01.20.427420 · doi:10.1101/2021.01.20.427420
Cited by
Items 301–400 of 967
Microbiota: A key factor affecting and regulating the efficacy of immunotherapy
Jiang, Y., Jia, D., Sun, Y., Ding, N., & Wang, L. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1508 · Cited by 22
Self-citationMicroecological regulation in HCC therapy: Gut microbiome enhances ICI treatment.
Liu, X.-L., Li, S., Ma, K.-X., & Wang, L. (2024) · Biochimica et Biophysica Acta - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167230 · Cited by 20
Self-citationHuangjing fructan: a kind of novel active carbohydrate with energy-supply function
Si, D., Liu, J., Shi, Y., Han, Z., Jin, P., Chen, D., & Si, J. (2025) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2025.105097 · Cited by 19
β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer
Liu, S., Guruprasad, P., Ramasubramanian, R., Madhu, B., Paruzzo, L., Han, K., Kelly, A. R., Shestov, A. A., Xu, H. N., Carturan, A., et al. (2026) · Cell · doi:10.1016/j.cell.2026.02.004 · Cited by 27
A probiotic supplement boosts response to cancer immunotherapy
Derosa, L., & Zitvogel, L. (2022) · Nature Medicine · doi:10.1038/s41591-022-01723-4 · Cited by 21
The Emerging Roles of Human Gut Microbiota in Gastrointestinal Cancer
Guo, Q., Qin, H., Liu, X., Zhang, X., Chen, Z., Qin, T., Chang, L., & Zhang, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915047 · Cited by 25
Self-citationEvolving concepts of host–pathobiont interactions in autoimmunity
Pereira, M. S., & Kriegel, M. A. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102265 · Cited by 21
Consistent Stool Metagenomic Biomarkers Associated with the Response To Melanoma Immunotherapy
Olekhnovich, E. I., Ivanov, A. B., Babkina, A. A., Sokolov, A. A., Игоревич, У. В., Fedorov, D. E., & Ilina, E. N. (2023) · mSystems · doi:10.1128/msystems.01023-22 · Cited by 21
Fecal Microbiota Transplantation as a Cancer Therapeutic
Stoff, R., Wolf, Y., & Boursi, B. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000651 · Cited by 23
Vandoni, G., D’Amico, F., Fabbrini, M., Mariani, L., Sieri, S., Casirati, A., Guardo, L. D., Vecchio, M. D., Anichini, A., Mortarini, R., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411611 · Cited by 18
The gut microbiome modulate response to immunotherapy in cancer
Jiang, S., Kang, Z., Chen, Y., & Fang, J. (2024) · Science China Life Sciences · doi:10.1007/s11427-023-2634-7 · Cited by 22
‘Know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors
Gunjur, A., Manrique-Rincón, A., Klein, O., Behren, A., Lawley, T. D., Welsh, S. J., & Adams, D. J. (2022) · The Journal of Pathology · doi:10.1002/path.5907 · Cited by 20
Unlocking the power of the microbiome for successful cancer immunotherapy
Clavijo-Salomon, M. A., & Trinchieri, G. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011281 · Cited by 18
Self-citationTumor microenvironment and macroenvironment: A new perspective on holistic oncology
Chen, Q., Jiang, K., Bronze, M. S., Li, M., Houchen, C. W., & Zhang, Y. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218076 · Cited by 24
Zhang, Y., Xu, X., Wang, S., Yin, X., Zhang, B., Zhu, Z., Ji, R., Zhu, J., He, H., Cheng, S., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013823 · Cited by 30
Self-citationYang, B.-Y., Zhao, F., Li, X., Zhao, M., Lv, J.-C., Shi, M., Li, J., Zhou, Z., Wang, J., & Song, J. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1133782 · Cited by 23
Lin, M., Sun, X. K., & Lv, L. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.04.007 · Cited by 22
Golčić, M., Simetić, L., Herceg, D., Blažičević, K., Jovanović, G. K., Dražić, I., Belančić, A., Skočibušić, N., Palčevski, D., Rubinić, I., et al. (2023) · Cancers · doi:10.3390/cancers15113052 · Cited by 18
Wei, J., Li, Z., Fan, Y., Feng, L., Zhong, X., Li, W., Guo, T., Ning, X., Li, Z., & Ou, C. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122001 · Cited by 18
Gut microbiota and immunotherapy of renal cell carcinoma
Bibbò, S., Porcari, S., Vecchio, L. E. D., Severino, A., Mullish, B. H., Ianiro, G., Gasbarrini, A., & Cammarota, G. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2268982 · Cited by 20
Metabolic heterogeneity in tumor microenvironment – A novel landmark for immunotherapy
Chen, C., Han, P., & Qing, Y. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103579 · Cited by 17
Lim, J. J., Reginald, K., Say, Y., Liu, M. H., & Chew, F. T. (2024) · European Journal of Nutrition · doi:10.1007/s00394-024-03524-6 · Cited by 22
Cesano, A., Augustin, R. C., Barrea, L., Bedognetti, D., Bruno, T. C., Carturan, A., Hammer, C., Ho, W. S., Kather, J. N., Kirchhoff, T., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008876 · Cited by 25
Self-citationXiao, Y., Yang, Y., Gao, S., Zhang, H., Wang, J., Lin, T., & Bai, Y. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1561235 · Cited by 19
How gut bacteria could boost cancer treatments
Erdmann, J. M. (2022) · Nature · doi:10.1038/d41586-022-01959-7 · Cited by 18
Rahman, G., Morton, J. T., Martino, C., Sepich‐Poore, G. D., Allaband, C., Guccione, C., Chen, Y., Hakim, D., Estaki, M., & Knight, R. D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.30.526328 · Cited by 20
Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis
Shang, J., Valle, D. M. D., Britton, G. J., Mead, K., Rajpal, U., Chen-Liaw, A., Mogno, I., Li, Z., Menon, R., Gonzalez‐Kozlova, E., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232079 · Cited by 17
The mechanisms and therapeutic potential of the microbiome-immune interface in cancer
Christina, B., Poongkuzhali, S., Muninathan, N., Bhaskaran, K., & Suresh, A. (2025) · Discover Biotechnology · doi:10.1007/s44340-025-00031-0 · Cited by 18
Leveraging beneficial microbiome-immune interactions via probiotic use in cancer immunotherapy
Jani, C., Edwards, K., Bhanushali, C. D., Zheng, X. X., Salazar, A. S., Lopes, G. D. L., Jr., & Watson, D. C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1713382 · Cited by 21
Extension of PERMANOVA to Testing the Mediation Effect of the Microbiome
Yue, Y., & Hu, Y. (2022) · Genes · doi:10.3390/genes13060940 · Cited by 21
Mattiola, I., & Diefenbach, A. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101724 · Cited by 19
Khosroshahi, R. A., Zeraattalab-Motlagh, S., Sarsangi, P., Nielsen, S. M., & Mohammadi, H. (2023) · British Journal Of Nutrition · doi:10.1017/s0007114523000910 · Cited by 22
Thomas, S., Dilbarov, N., Kelly, J., Mercogliano, G., & Prendergast, G. C. (2023) · Scientific Reports · doi:10.1038/s41598-023-38830-2 · Cited by 18
Lifestyle and host determinants of antitumor immunity and cancer health disparities
Swaby, A. M., Atallah, A., Varol, O., Cristea, A., & Quail, D. F. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.08.007 · Cited by 19
Role of the Microbiota in Skin Neoplasms: New Therapeutic Horizons
Savoia, P., Azzimonti, B., Rolla, R., & Zavattaro, E. (2023) · Microorganisms · doi:10.3390/microorganisms11102386 · Cited by 19
Identification of gut microbiota dysbiosis in bullous pemphigoid under different disease activity
Hu, X., Wu, Q., Fan, Y., Guo, F., Li, S., Zhang, S., & Zuo, Y. (2023) · Experimental Dermatology · doi:10.1111/exd.14965 · Cited by 15
Diet-driven microbiome changes and physical activity in cancer patients
Čierniková, S., Ševčíková, A., Števurková, V., & Mego, M. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1285516 · Cited by 19
Eating away cancer: the potential of diet and the microbiome for shaping immunotherapy outcome
Nguyen, N.-T. A., Jiang, Y., & McQuade, J. L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1409414 · Cited by 23
Self-citationImpact of the Lung Microbiota on Development and Progression of Lung Cancer
Belaïd, A., Roméo, B., Rignol, G., Benzaquen, J., Audoin, T., Vouret‐Craviari, V., Brest, P., Varraso, R., von Bergen�, M., Marquette, C., et al. (2024) · Cancers · doi:10.3390/cancers16193342 · Cited by 18
Sitthideatphaiboon, P., Somlaw, N., Zungsontiporn, N., Ouwongprayoon, P., Sukswai, N., Korphaisarn, K., Poungvarin, N., Aporntewan, C., Hirankarn, N., Vinayanuwattikun, C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-79339-6 · Cited by 20
Li, X., An, N., Chen, H., & Liu, D. (2025) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1533081 · Cited by 16
The human microbiome: redefining cancer pathogenesis and therapy
Adlakha, Y. K., & Chhabra, R. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03787-x · Cited by 25
The Gut Microbiome Controls Liver Tumors via the Vagus NervePreprint
Bauer, K. C., Trehan, R., Ruf, B., Myojin, Y., Benmebarek, M.-R., Ma, C., Seifert, M., Nur, A., Qi, J., Huang, P., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.23.576951 · Cited by 20
Self-citationZwolschen, J. W., Tomassen, M. M. M., Vos, A. P., & Schols, H. A. (2024) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2024.123052 · Cited by 16
Wang, C., He, Y., Zhao, G., Ouyang, X., Wang, S., Chen, Y., Li, C., Jiang, Y., Xiong, T., 何永武, et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2489072 · Cited by 19
Age- and diet-instructed metabolic rewiring of the tumor–immune microenvironment
Plata-Gómez, A. B., & Ho, P. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241102 · Cited by 20
Gut microbiome and gastric cancer: microbial interactions and therapeutic potential
El-Ghannam, M., Hassanien, M. H., Ameen, Y. A., Turky, E. A., ELattar, G. M., Ray, A. A. E., & Eltalkawy, M. D. (2025) · Gut Pathogens · doi:10.1186/s13099-025-00729-w · Cited by 16
Advancements in understanding tumor‑resident bacteria and their application in cancer therapy
Luo, Y., Huang, X., Wang, R., Lin, Y., Sun, J., Li, K., Wang, D. Y., Yan, Y., & Qiao, Y. (2025) · Military Medical Research · doi:10.1186/s40779-025-00623-1 · Cited by 31
Self-citationQiao, S., Li, T.-T., Jeong, M., Chuanfa, L. I. U., Mizutani, S., Hwang, S.-M., Li, Y., Lyu, M., Nishiyama, K., Tang, Y.-A., et al. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2025.12.003 · Cited by 17
Kim, A. J., Hong, D. S., & George, G. C. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102408 · Cited by 21
Agrawal, M. Y., Gaikwad, S. R., Srivastava, S., & Srivastava, S. (2022) · Cancers · doi:10.3390/cancers14225482 · Cited by 17
Gut microbiota: A novel and potential target for radioimmunotherapy in colorectal cancer
Yuan, H., Gui, R., Wang, Z., Fang, F., & Zhao, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1128774 · Cited by 18
Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
Zhou, Y., & Li, H. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1227049 · Cited by 15
Self-citationNon-pharmaceutical interventions to optimize cancer immunotherapy
Boesch, M., Baty, F., Rassouli, F., Kowatsch, T., Joerger, M., Früh, M., & Brutsche, M. H. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2255459 · Cited by 19
Nutrient-Based Approaches for Melanoma: Prevention and Therapeutic Insights
Dong, Y., Wei, J., Yang, F., Qu, Y., Huang, J., & Shi, D. (2023) · Nutrients · doi:10.3390/nu15204483 · Cited by 17
Diet and immune response: how today’s plate shapes tomorrow’s health
Siracusa, F., Tintelnot, J., Cortesi, F., & Gagliani, N. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.10.010 · Cited by 15
Microbiota configuration determines nutritional immune optimization
Han, S., Stacy, A., Corral, D., Link, V. M., Siqueira, M. K. D., Chi, L., Teijeiro, A., Yong, D., Pérez‐Chaparro, P. J., Bouladoux, N. J., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2304905120 · Cited by 17
Causal roles of skin microbiota in skin cancers suggested by genetic study
Zhu, Y., Liu, W., Wang, M., Wang, X., & Wang, S. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1426807 · Cited by 15
Jurlander, R. S., Guldbrandt, L. M., Holmstroem, R. B., Madsen, K. S., Donia, M., Haslund, C. A., Schmidt, H., Bastholt, L., Ruhlmann, C. H. B., Svane, I. M., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115053 · Cited by 20
Ren, S., Zhang, Y., Wang, X., Su, J., Wang, X., Yuan, Z., He, X., Guo, S., Chen, Y., Deng, S., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1526967 · Cited by 22
Pharmacomicrobiomics in precision cancer therapy: bench to bedside
Ngoc, K. L., Pham, T. T. H., Nguyen, T. K., & Huong, P. T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1428420 · Cited by 20
Gut microbiome in gastrointestinal neoplasms: from mechanisms to precision therapeutic strategies
Song, J., Zhang, W., & Wang, D. (2025) · Gut Pathogens · doi:10.1186/s13099-025-00734-z · Cited by 18
The multi-kingdom cancer microbiome
Dohlman, A. B., Pan, X., Zitvogel, L., & Iliev, I. D. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02103-7 · Cited by 18
Microbial metabolites in tumor epigenetic regulation
Zhang, W., Zhang, H., Liao, Y., Jiang, S., Zhang, H., Huang, C., Song, Z., Zhao, R., Lü, P., Kang, X., et al. (2026) · iMeta · doi:10.1002/imt2.70115 · Cited by 19
The difference of human gut microbiome in colorectal cancer with and without metastases
Sun, L., Zhu, Z., Jia, X., Ying, X., Wang, B., Wang, P., Zhang, S., & Yu, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.982744 · Cited by 20
Olimpio, F. R. D. S., Andreata‐Santos, R., Rosa, P. C., Alves, W. D. S., Oliveira, C. R., & Aimbire, F. (2022) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-022-09998-2 · Cited by 15
González-Brito, A., & Uribe‐Herranz, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1083303 · Cited by 14
Characterization of intratumor microbiome in cancer immunotherapy
Zhang, Z., Gao, Q., Ren, X., Luo, M., Liu, Y., Liu, P., Liu, Y., Ye, Y., Chen, X., Liu, H., et al. (2023) · The Innovation · doi:10.1016/j.xinn.2023.100482 · Cited by 21
Tsakmaklis, A., Farowski, F., Zenner, R., Lesker, T. R., Strowig, T., Schlößer, H., Lehmann, J. M., von Bergwelt‐Baildon, M., Mauch, C., Schlaak, M. S., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11551-5 · Cited by 14
Roichman, A., Reyes‐Castellanos, G., Chen, Z., Chen, Z., Mitchell, S. J., MacArthur, M. R., Sawant, A., Levett, L., Powers, J. R., Burgo, V., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-4378 · Cited by 16
Issa, M., Tang, J., Guo, Y., Coss, C. C., Mace, T. A., Bischof, J. J., Phelps, M. A., Presley, C. J., & Owen, D. H. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2094772 · Cited by 15
Liu, L., Zhang, T., Sui, Y., Li, G., Liu, L., Lu, T., Tan, H., Sun, B., Li, X., & Li, L. (2023) · Microbial Pathogenesis · doi:10.1016/j.micpath.2023.106035 · Cited by 16
JAMS - A framework for the taxonomic and functional exploration of microbiological genomic dataPreprint
McCulloch, J. A., Badger, J. H., Cannon, N., Rodrigues, R. R., Valencia, M. E., Barb, J. J., Fernandes, M. R., Balaji, A. K., Crowson, L., Ó’hUigín, C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.03.531026 · Cited by 16
Self-citationRole of Gut Microbiome in Oncogenesis and Oncotherapies
Peddireddi, R. S. S., Kuchana, S. K., Kode, R., Khammammettu, S., Koppanatham, A., Mattigiri, S., Gobburi, H., & Alahari, S. K. (2025) · Cancers · doi:10.3390/cancers18010099 · Cited by 15
Training the microbiota to increase immune checkpoint blockade and to reduce toxicity
Rescigno, M. (2023) · European Journal of Immunology · doi:10.1002/eji.202250183 · Cited by 15
The Gut Microbiome and Metastatic Renal Cell Carcinoma
Meza, L., Feng, M., Lee, K., Sperandio, R., & Pal, S. K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041502 · Cited by 12
The Microbiome and Liver Cancer
Myojin, Y., & Greten, T. F. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000646 · Cited by 13
The Microbiome in Advanced Melanoma: Where Are We Now?
Fortman, D. D., Hurd, D. E., & Davar, D. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01431-3 · Cited by 14
Microbiome modulates immunotherapy response in cutaneous squamous cell carcinoma
Voigt, A. Y., Walter, A., Young, T. H., Graham, J. P., Bittencourt, B. M. B., Pulido, Á. D. M., Prieto, K., Tsai, K. Y., Sundberg, J. P., & Oh, J. (2023) · Experimental Dermatology · doi:10.1111/exd.14864 · Cited by 13
Advances in the role of gut microbiota in the regulation of the tumor microenvironment (Review)
Xinyuan, T., Yu, L., Jianping, S., Rongwei, Z., Ruiwen, S., Ye, Z., Zhao, J., Chun-fang, T., Hongwei, C., & Haibin, G. (2023) · Oncology Reports · doi:10.3892/or.2023.8618 · Cited by 14
Gorgulho, J., Roderburg, C., Beier, F., Bokemeyer, C., Brümmendorf, T. H., Luedde, T., & Loosen, S. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1206953 · Cited by 14
Influence of tumor mycobiome on cancer pathogenesis (Review)
Liu, W., Li, Z., Li, X., Cao, H., Jiang, H., Niu, Q., & Hu, B. (2023) · Oncology Letters · doi:10.3892/ol.2023.14128 · Cited by 13
Gut microbiota in cancer: insights on microbial metabolites and therapeutic strategies
Chen, Y., Wang, X., Ye, Y., & Ren, Q. (2023) · Medical Oncology · doi:10.1007/s12032-023-02249-6 · Cited by 14
Gao, S., Zhao, X., Leng, Y., & Xia, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-52066-8 · Cited by 16
Standards for fecal microbiota transplant: Tools and therapeutic advances
Belotserkovsky, I., Stabryla, L. M., Hunter, M. E., Allegretti, J. R., Callahan, B. J., Carlson, P. E., Daschner, P. J., Goudarzi, M., Guyard, C., Jackson, S. A., et al. (2024) · Biologicals · doi:10.1016/j.biologicals.2024.101758 · Cited by 14
Self-citationThe Role of Bacteria in Central Nervous System Tumors: Opportunities and Challenges
Zhang, R., Li, X., & Zhang, S. (2024) · Microorganisms · doi:10.3390/microorganisms12061053 · Cited by 13
Targeting the Gut Microbiome to Improve Immunotherapy Outcomes: A Review
David, A., & Ari, S. L. (2024) · Integrative Cancer Therapies · doi:10.1177/15347354241269870 · Cited by 16
Fecal microbial transplants as investigative tools in cancer
Bohm, M. S., Ramesh, A. V., Pierre, J. F., Cook, K. L., Murphy, E. A., & Makowski, L. (2024) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00171.2024 · Cited by 15
The therapeutic promise of probiotic Bacteroides fragilis (BF839) in cancer immunotherapy
Peng, K., Li, Y., Yang, Q., Yu, P., Zeng, T., Lin, C., Deng, Y., & Chen, J. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1523754 · Cited by 17
Nutrition and Microbiome Interactions in Human Cancer
Daschner, P. J., Ross, S., Seifried, H. E., Kumar, A., & Flores, R. (2022) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2022.10.004 · Cited by 14
Garcia, M. B., Schadler, K., Chandra, J., Clinton, S. K., Courneya, K. S., Cruz‐Monserrate, Z., Daniel, C. R., Dannenberg, A. J., Demark‐Wahnefried, W., Dewhirst, M. W., et al. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21773 · Cited by 17
Self-citationTanaka, I., Yano, Y., Mori, M., Manabe, S., & Fukuo, K. (2024) · Scientific Reports · doi:10.1038/s41598-024-51967-y · Cited by 15
Biomarkers and immunotherapy: where are we?
Fontsa, M. L., Padonou, F., & Willard-Gallo, K. E. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000891 · Cited by 16
Zhang, N., Ren, Y., & Xu, Y. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1627949 · Cited by 24
Zhang, Y., & Liu, Z. (2025) · Advanced Science · doi:10.1002/advs.202508692 · Cited by 18
Host and microbiome lipid metabolism in colorectal cancer development and therapy
Evora, G. M., Brauer, M., & Letellier, E. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.08.005 · Cited by 18
Stone, S., McPherson, J. P., Kulkarni, R. P., & Young, A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00890-z · Cited by 15
Zheng, S., Li, K.-Z., Feng, G., Wang, Y.-T., Jia-ning, W. A. N. G., Li, S., & Sun, Y.-D. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02513-5 · Cited by 17
Emerging target discovery and drug repurposing opportunities in chordoma
Freed, D. M., Sommer, J., & Punturi, N. B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1009193 · Cited by 11
Cai, M., Deng, H., Sun, H., Si, W., Li, X., Hu, J., Huang, M., & Fan, W. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1052824 · Cited by 12
Self-citation
Metadata
- Authors
- Spencer, C. N., McQuade, J. L., Gopalakrishnan, V., McCulloch, J. A., Vetizou, M., Cogdill, A. P., Khan, M. A. W., Zhang, X., White, M. G., Peterson, C. B., Wong, M. C., Morad, G., Rodgers, T., Badger, J. H., Helmink, B. A., Andrews, M. C., Rodrigues, R. R., Morgun, A., Kim, Y. S., Roszik, J., Hoffman, K. L., Zheng, J., Zhou, Y., Medik, Y. B., Kahn, L. M., Johnson, S., Hudgens, C. W., Wani, K., Gaudreau, P.-O., Harris, A. L., Jamal, M. A., Baruch, E. N., Perez-Guijarro, E., Day, C.-P., Merlino, G., Pazdrak, B., Lochmann, B. S., Szczepaniak-Sloane, R. A., Arora, R., Anderson, J., Zobniw, C. M., Posada, E., Sirmans, E., Simon, J., Haydu, L. E., Burton, E. M., Wang, L., Dang, M., Clise-Dwyer, K., Schneider, S., Chapman, T., Anang, N.-A. A. S., Duncan, S., Toker, J., Malke, J. C., Glitza, I. C., Amaria, R. N., Tawbi, H. A., Diab, A., Wong, M. K., Patel, S. P., Woodman, S. E., Davies, M. A., Ross, M. I., Gershenwald, J. E., Lee, J. E., Hwu, P., Jensen, V., Samuels, Y., Straussman, R., Ajami, N. J., Nelson, K. C., Nezi, L., Petrosino, J. F., Futreal, P. A., Lazar, A. J., Hu, J., Jenq, R. R., Tetzlaff, M. T., Yan, Y., Garrett, W. S., Huttenhower, C., Sharma, P., Watowich, S. S., Allison, J. P., Cohen, L., Trinchieri, G., Daniel, C. R., & Wargo, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- National Institutes of Health (US)
- Laboratory of Integrative Cancer Immunology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
- Frederick National Laboratory for Cancer Research (US)
- Oregon State University (US)
- Baylor College of Medicine (US)
- Queen's University (CA)
- The University of Texas Health Science Center at Houston (US)
- Laboratory of Cancer Biology and Genetics, CCR, NCI, NIH, Bethesda, MD 20892, USA.
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Harvard University (US)
- Weizmann Institute of Science (IL)
- European Institute of Oncology (IT)
- Columbia University (US)
- University of California, San Francisco (US)
- Broad Institute (US)
- Corresponding author
- Spencer, Christine N.
- McQuade, Jennifer L.
- Gopalakrishnan, Vancheswaran
- McCulloch, John A.
- Cogdill, Alexandria P.
- Cohen, Lorenzo
- Trinchieri, Giorgio
- Daniel, Carrie R.
- Wargo, Jennifer A.
- ORCID
- Spencer, Christine N.
- McQuade, Jennifer L.
- Gopalakrishnan, Vancheswaran
- McCulloch, John A.
- Vetizou, Marie
- Cogdill, Alexandria P.
- Khan, Md A. Wadud
- Zhang, Xiaotao
- White, Michael G.
- Peterson, Christine B.
- Wong, Matthew C.
- Morad, Golnaz
- Rodgers, Theresa
- Badger, Jonathan H.
- Helmink, Beth A.
- Andrews, Miles C.
- Rodrigues, Richard R.
- Morgun, Andrey
- Kim, Young S.
- Roszik, Jason
- Hoffman, Kristi L.
- Zhou, Yifan
- Medik, Yusra B.
- Kahn, Laura M.
- Johnson, Sarah
- Hudgens, Courtney W.
- Wani, Khalida
- Gaudreau, Pierre-Olivier
- Harris, Angela L.
- Jamal, Mohamed A.
- Baruch, Erez N.
- Perez-Guijarro, Eva
- Day, Chi-Ping
- Merlino, Glenn
- Pazdrak, Barbara
- Lochmann, Brooke S.
- Arora, Reetakshi
- Anderson, Jaime
- Zobniw, Chrystia M.
- Simon, Julie
- Haydu, Lauren E.
- Burton, Elizabeth M.
- Wang, Linghua
- Dang, Minghao
- Clise-Dwyer, Karen
- Schneider, Sarah
- Anang, Nana-Ama A. S.
- Toker, Joseph
- Malke, Jared C.
- Glitza, Isabella C.
- Amaria, Rodabe N.
- Tawbi, Hussein A.
- Diab, Adi
- Wong, Michael K.
- Patel, Sapna P.
- Woodman, Scott E.
- Davies, Michael A.
- Ross, Merrick I.
- Gershenwald, Jeffrey E.
- Lee, Jeffrey E.
- Hwu, Patrick
- Jensen, Vanessa
- Samuels, Yardena
- Straussman, Ravid
- Ajami, Nadim J.
- Nelson, Kelly C.
- Nezi, Luigi
- Petrosino, Joseph F.
- Futreal, P. Andrew
- Lazar, Alexander J.
- Hu, Jianhua
- Jenq, Robert R.
- Tetzlaff, Michael T.
- Yan, Yan
- Garrett, Wendy S.
- Huttenhower, Curtis
- Sharma, Padmanee
- Watowich, Stephanie S.
- Allison, James P.
- Cohen, Lorenzo
- Trinchieri, Giorgio
- Daniel, Carrie R.
- Wargo, Jennifer A.
- Venue
- Science
- Published
- 2021-12-24
- Volume
- 374
- Issue
- 6575
- Pages
- 1632-1640
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8970537
- OpenAlex
- W4200001874
- Cited by
- 966
- References
- 70
- Citations by year
- 2026: 236 · 2025: 216 · 2024: 172 · 2023: 212 · 2022: 130
- FWCI
- 46.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Research UK (27140)
- National Heart, Lung, and Blood Institute (R01HL124112)
- National Cancer Institute (P50CA221703, R01CA219896, F32CA260769, U54CA224070, T32CA009599, R25CA203650, P30CA016672, P30CA013696)
- National Institute of Allergy and Infectious Diseases (R56AI109294, R01AI133822, R01AI143886, R01AI109294)
- National Institute of Environmental Health Sciences (P30ES030285)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- dietary fiber, probiotics, gut microbiota, melanoma, immune checkpoint blockade, anti-PD-1 therapy, treatment response, progression-free survival, fecal microbiota, tumor microenvironment, interferon-gamma, cytotoxic T lymphocytes, low-fiber diet
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Progression-Free Survival, Immune Checkpoint Inhibitors, Animals, Dietary Fiber, Fatty Acids, Volatile, Feces, Female, Humans, Immunotherapy, Male, Melanoma, Melanoma, Experimental, Mice, Inbred C57BL, T-Lymphocytes, Cohort Studies, Probiotics, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.